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Abstract
The occurrence of blood-borne prion transmission incidents calls for identification of potential prion carriers. However,
current methods for intravital diagnosis of prion disease rely on invasive tissue biopsies and are unsuitable for large-scale
screening. Sensitive biomarkers may help meeting this need. Here we scanned the genome for transcripts elevated upon
prion infection and encoding secreted proteins. We found that a1-antichymotrypsin (a1-ACT) was highly upregulated in
brains of scrapie-infected mice. Furthermore, a1-ACT levels were dramatically increased in urine of patients suffering from
sporadic Creutzfeldt-Jakob disease, and increased progressively throughout the disease. Increased a1-ACT excretion was
also found in cases of natural prion disease of animals. Therefore measurement of urinary a1-ACT levels may be useful for
monitoring the efficacy of therapeutic regimens for prion disease, and possibly also for deferring blood and organ donors
that may be at risk of transmitting prion infections.
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Introduction
The prion [1] is the infectious agent causing transmissible
spongiform encephalopathies, which include sporadic (sCJD) and
variant Creutzfeldt-Jakob disease (vCJD) in humans, scrapie in
sheep, bovine spongiform encephalopathy (BSE) in cattle, and
chronic wasting disease (CWD) in cervids [2]. Although prions
may replicate in extraneural tissues [3,4], cellular damage is
essentially limited to the central nervous system (CNS). The
molecular mechanisms underlying prion replication and subse-
quent neural damage are not entirely understood. No effective
therapeutic strategies are available.
An essential component of the prion is PrPSc, an abnormally
folded, aggregated isoform of the host protein PrPC [5]. To date,
all validated laboratory assays for prion diseases rely on the
immunochemical detection of PrPSc. These methods are highly
specific, but suffer from limited sensitivity as one infectious prion
may be equivalent to ,102 aggregated PrPSc molecules [6] –
which is much lower than the threshold of detection of most
immunoassays. Additionally, the presence of excess PrPC in
complex biological fluids may confound immunochemical detec-
tion, even if biophysical detection methods are employed.
Consequently, while positive detection of PrPSc suffices to establish
a firm diagnosis of prion infection, its absence by no means rules
out the presence of prion infectivity.
The hundreds of iatrogenic transmissions through organ
extracts [7], contaminated surgical instruments [8], and probably
through blood transfusions [9,10] have tragically highlighted the
current inability of diagnosing presymptomatic prion infections.
While there has been recent progress in detecting low amounts of
PrPSc in blood of experimentally inoculated hamsters by protein
misfolding cyclic amplification [11], it is unknown whether this
technology possesses adequate sensitivity and throughput for prion
detection in human blood.
The use of surrogate biomarkers represents a diagnostic strategy
fundamentally different to those delineated above. Since they
typically identify secondary host reactions, surrogate biomarkers of
prion infection cannot aspire at matching the specificity of PrPSc
detection. On the other hand, surrogate biomarkers may be useful
for identifying subjects at risk, and specifying acceptance or
deferral of blood donations. In such cases high sensitivity (i.e. the
identification of all suspect individuals) is more important than
absolute diagnostic specificity, as the latter can be supplied by
confirmatory assays.
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Surrogate biomarkers may represent proteins that are differen-
tially expressed or represented in body fluids of prion-affected
individuals. S-100, neuron-specific enolase, and 14-3-3 protein
have been reported to be elevated in cerebrospinal fluid (CSF) of
sCJD patients [12,13,14]. These proteins may represent conse-
quences of CNS damage and neuronal death. The cysteine
proteinase inhibitor cystatin C was also reported to be elevated in
CSF of sCJD patients [15,16].
In an effort to characterize the transcriptome of prion-infected
murine tissues, we have searched for transcripts which (1) are
profoundly upregulated and (2) whose predicted gene products
contain secretory leader peptides. One transcript fulfilling these
criteria is serpin-a3n, the murine homolog of human alpha-1-
antichymotrypsin (a1-ACT), a serine proteinase inhibitor which
has been previously implicated in the pathogenesis of Alzheimer’s
disease [17,18] and which has been reported to be a candidate
plasma and CSF biomarker of Alzheimer’s disease (AD)
[19,20,21,22]. In the present study, we sought to investigate the
potential usefulness of a1-ACT, and to compare it to the recently
proposed cystatin C, as candidate biomarker for prion diagnostics
in body fluids.
Results
Transcriptional microarray analysis of whole brains from
prion-infected and mock-infected mice
We have performed a genomie-wide interrogation of the brain
transcriptome of C57Bl/6 mice at 145 days post inoculation (dpi)
intraperitoneally (i.p.) with scrapie prions (RML strain, passage 5).
In this model of murine scrapie, the incubation period between the
date of inoculation and the onset of terminal clinical signs of
scrapie is approximately 200 dpi.
The extracerebral inoculation route and the 145 dpi time point
were chosen in order to minimize any severe histopathological
changes to the brain, thereby lowering the occurrence of unspecific
transcriptional changes. This goal was essentially achieved, since the
vast majority of transcripts were quantitatively unaffected in prion-
infected vs. mock-infected brains. When applying stringent filter
settings, we identified a total of only 77 transcripts which appeared
up- or down-regulated with a confidence limit of .90% and
Student’s t test p values of ,0.05 (Table S1 online).
The majority of these changes in expression were modest
(22.04 to +3.41 fold). Some transcripts, including glial fibrillary
acidic protein, complement components, and beta-2-microglobu-
lin, had been previously identified as being differentially expressed
following prion infection [23,24,25,26,27]. Serpin-a3n was iden-
tified as a very highly overexpressed transcript in brains of prion-
infected mice before the onset of clinical signs. The latter
observation was particularly intriguing in view of the fact that
Serpin-a3n encodes a secreted protein which is detectable in a
variety of body fluids. This suggested that Serpin-a3n may
represent a candidate biomarker for preclinical diagnosis of prion
infections in cerebrospinal fluid (CSF) or serum.
Serpin-a3n/a1-ACT transcription in brain during prion
pathogenesis
Both Northern hybridization and QPCR confirmed that whole-
brain transcription of Serpin-a3n increased progressively during the
course of prion infections. Significant overexpression was detected
already between 120 and 130 dpi (Fig. 1A), and reached levels of up
to 17-fold higher than controls by 190 dpi (Fig. 1B). Therefore,
Serpin-a3n ranks among the most highly upregulated transcripts in
prion-infected brains. For comparison, glial fibrillary acidic protein
transcripts, a marker of reactive astrogliosis often used to quantitate
brain damage, only reached levels of #8-fold higher than controls
by late-stage of prion pathogenesis (Fig. 1A & B).
Having established that whole-brain Serpin-a3n RNA was
markedly elevated upon prion infection, we investigated its
regional expression in specific segments of the CNS. We found
that Serpin-a3n RNA was upregulated 6-fold higher in spinal cord,
3-fold in cerebellum, and 5-fold in cortex of prion-infected mice by
140 dpi (Fig. 1C). For comparison, GFAP RNA was overexpressed
3-fold in spinal cord and 4-fold in cerebellum and cortex of the
same mice (Fig. 1A & C). The very high upregulation found in the
spinal cord may be related to the i.p. route of inoculation, which
favors prion entry into the thoracic segments of the spinal cord.
The human homologue of Serpin-a3n is a1-anti-chymotrypsin (a1-
ACT). We investigated a1-ACT mRNA in post-mortem occipital
cortex of patients suffering from AD and sporadic CJD (sCJD). Brains
of non-demented, age-matched patients were used for control (Fig 1D,
left panel). Similarly to the observations reported above for prion-
infected mice, a1-ACTRNA was significantly elevated in the CNS of
sCJD patients (p=0.019, Fig. 1D).
Cystatin C and a1-ACT levels are unaltered in AD and
sCJD patient plasma
Plasma cystatin C and a1-ACT were measured by sandwich
ELISA and expressed either as raw concentration (ng/ml), or
relative to total plasma protein (Table 1). For control, we assayed
plasma from individuals with non-neurodegenerative diseases.
Samples were from patients of similar age and gender distribution
to the AD and sCJD groups, and were obtained at mid- and late-
stage of disease. However, no alterations in the plasma
concentration of either cystatin C or a1-ACT were evident in
the sCJD and AD groups relative to controls.
Cystatin C and a1-ACT in cerebrospinal fluid
We used sandwich ELISA to measure cystatin C and a1-ACT in
the CSF of patients suffering from AD, sCJD and vCJD at mid- to
late-clinical stage of disease. Values were expressed either as
absolute concentrations or relative to total CSF protein (Table 2).
The age and gender composition of sCJD patients, AD patients, and
control group A (patients suffering from non-neurodegenerative
diseases) was similar (p.0.05). Control group B represents patients
of similar age and gender distribution to the vCJD collective, and
was derived from patients initially suspected of having CJD but later
determined to suffer from other diseases. Since vCJD tends to occur
at a much younger age than sCJD, the average age of the two
control groups is very different. Interestingly, the total CSF protein
concentration and the concentrations of cystatin C were different
between control groups A and control group B, suggesting that they
may be modulated by an age-dependent process (Table 3).
In contrast to previous reports [15,16], we found no elevated CSF
levels of cystatin C in sCJD and vCJD patients (Table 2).
Furthermore, Western blot analysis using immunoreagents derived
from the same source as in one of these studies [16] showed levels of
cystatin C in CSF of sCJD patients indistinguishable from non-CJD
controls (Fig. 2). a1-ACT concentrations were then divided by total
CSF protein concentration, and each patient collective was
compared to the appropriate control group. After the latter
normalization we found a moderate, yet significant, elevation of
a1-ACT in CSF samples of sCJD patients (46% , p,0.001, Table 2).
Urinary levels of cystatin C, a1-antichymotrypsin and a1-
microglobulin
The urinary concentration of cystatin C and a1-ACT in AD,
sCJD and vCJD patients at mid-to-late stages of disease was
Prion Disease Biomarker
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Figure 1. Serpin-a3n/a1-ACT transcripts in brain during prion pathogenesis. (A) Northern hybridization analysis of Serpin-a3n RNA
expression levels in whole brains of mice throughout pathogenesis following intraperitoneal inoculation with either mock inoculum or inoculum
containing 6 log LD50 RML5 mouse prions (dpi; days post-inoculation). For comparison, expression levels of Glial fibrillary acidic protein (Gfap) RNA
are also shown. Expression levels were normalized to 18S rRNA levels. Differential expression of Serpin-a3n transcripts is evident between 120 dpi and
130 dpi in whole brain. For comparison, increased RNA levels of Gfap, traditionally thought of as one of the largest gene expression changes during
prion pathogenesis, is evident between 120 dpi and 130 dpi and rises to approximately 8-fold by 190 dpi. (B) DNAse-treated total RNA was prepared
from whole brains of mock- or prion-inoculated mice at 45, 100, 145 or 190 dpi and used for qPCR analyses. Serpin-a3n RNA levels are progressively
elevated in brains of prion infected mice throughout pathogenesis and at 145dpi and 190 dpi are approximately 9-fold and 17-fold higher compared
to mock inoculated controls. Murine measurements encompass a total of three biological replicates. All transcript levels were normalized to beta-
actin and expressed relative to mock-inoculated mice or non-neurodegenerative controls. In the murine model of prion disease utilized, terminal
signs are evident at approximately 200–210 dpi. Error bars represent standard deviations of three biological replicates. (C) Northern hybridization
analysis of Serpin-a3n and Gfap in CNS areas of prion infected and uninfected mice at 90 dpi, 100 dpi and 140 dpi stages of pathogenesis. Equivalent
loading of RNA is indicated by 18S rRNA levels. Abbreviations: Cb, cerebellum; Sc, spinal cord; Ob, olfactory bulb; Cx, cortex. Cystatin F differential
expression in prion infected mice is first evident in the spinal cord between 90 dpi and 100 dpi (8-fold increase). By 140 dpi, Sepina3n RNA levels in
spinal cord, cerebellum and cortex are approximately 6-fold, 3-fold and 5-fold respectively. For comparison, by 140 dpi, Gfap RNA levels, an indicator
of gliosis, in spinal cord, cerebellum and cortex are approximately 3-fold, 4-fold and 4-fold respectively. No change in expression levels of these
transcripts in olfactory bulb at any of the stages of pathogenesis analyzed here. (D) DNAse-treated total RNA was prepared from occipital cortex
obtained at autopsy from patients suffering from non-neurodegenerative diseases (Control), Alzheimer’s disease (AD), or sporadic CJD (sCJD)
patients. Left panel: Age distribution of the patients in each group at time of death. Right panel: box and whisker plots indicating upper- and
lowermost values with mean and 75th percentile for eight patients within each group. Values were tested for statistical significance using Student’s t
test (two samples, equal variance). Triplicate qPCR reactions were performed for each sample.
doi:10.1371/journal.pone.0003870.g001
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determined by sandwich ELISA. Similarly to the CSF analysis
reported above, urinary a1-ACT concentrations of sCJD patients
were compared to those of AD patients and of control group A.
We found dramatically elevated urinary a1-ACT in sCJD patients
(Table 3, Figure 3). This was particularly evident when a1-ACT
concentrations were normalized to albumin or to creatinine
(p,0.001), but it reached significance even when raw concentra-
tions were analyzed without any attempt at normalization
(p,0.05).
We considered several artifactual scenarios which may have led
to the above observations. Since both cystatin C and a1-ACT are
present in urine at concentrations far below those observed in
Table 1. Plasma concentration of Cystatin C and a1-ACT in patients suffering from AD or sCJD.
Control (n = 10) AD (n=10) sCJD (n=10)
Patient age (years) 70.90 (1.98) 77.40 (2.12) 69.00 (4.98)
Total protein (g/L) 65.79 (1.75) 66.16 (2.40) 64.31 (2.52)
Cystatin C (mg/L) 1310.26 (91.64) 1394.46 (59.00) 1381.25 (108.51)
Cystatin C (ng/mg plasma protein) 19.93 (1.23) 21.15 (0.71) 21.65 (1.68)
a1-ACT (mg/L) 978.42 (61.30) 931.08 (88.28) 1000.59 (96.48)
a1-ACT (mg/mg plasma protein) 14.80 (0.67) 14.15 (1.24) 15.86 (1.85)
Plasma levels of cystatin C and a1-ACT. Cystatin C and a1-ACT levels were measured in plasma of sCJD patients, as well as in age and gender-matched collectives of
healthy persons and AD patients by ELISA. Numbers in parenthesis represent s.e.m.
doi:10.1371/journal.pone.0003870.t001
Table 2. Cystatin C and a1-ACT in patient cerebrospinal fluid.
Control A (n =10) AD (n=10) sCJD (n=8) Control B (n =8) vCJD (n=10)
Patient age (years) 66.20 (4.36) 67.44 (3.17) 66.50 (3.91) 37.25 (4.25) 31.50 (2.44)
Total protein (mg/L) 871.58 (39.63) 771.94 (47.56) 917.14 (227.61) 500.87 (82.02) 452.99 (61.08)
Cystatin C (mg/L) 3875.00 (362.90) 3278.89 (345.50) 3868.75 (333.85) 4413.75 (642.03) 3113.00 (328.04)
Cystatin C (ng/mg CSF protein) 4471.19 (402.78) 4275.30 (406.21) 5275.04 (793.47) 9781.25 (1254.68) 8005.71 (1243.42)
a1-ACT (mg/L) 7.67 (0.33) 7.17 (0.45) 11.86 (3.05) 10.31 (2.86) 6.97 (0.35)
a1-ACT (mg/mg CSF protein) 8.90 (0.43) 9.30 (0.17) 12.98 (0.71)** 21.94 (3.85) 17.41 (1.84)
CSF levels of cystatin C and a1-ACT. Levels of cystatin C and a1-ACT were measured in patient CSF by ELISA and expressed as quantity per ml fluid or relative to total
CSF protein. Values from sCJD patient CSF were compared to values obtained from CSF of both AD patients and healthy control groups of comparable age and gender
distribution within groups (control group A). Since vCJD is typically prevalent in patients of a younger age, values for vCJD CSF were compared to those obtained from
patients of comparable age (control group B). Numbers in parenthesis represent s.e.m.
doi:10.1371/journal.pone.0003870.t002
Table 3. Cystatin C, a1-ACT and a1-microglobulin in the urine of patients.
Control A (n =10) AD (n=9) sCJD (n=29) Control B (n =10) vCJD (n=6) Control C (n =13)
Patient age (years) 73.50 (2.00) 80.20 (2.14) 67.52 (1.76) 23.50 (0.60) 28.67 (2.47) 52.69 (6.43)
Cystatin C (mg/L) 43.18 (3.46) 46.80 (8.00) 74.88 (9.87) 62.78 (18.92) 120.29 (29.79) 69.86 (18.74)
Cystatin C (mg/mg albumin) 6.21 (1.42) 5.67 (0.90) 4.18 (0.76) 7.00 (2.13) 15.00 (4.14) 7.52 (1.82)
Cystatin C (mg/g Creatinine) 40.74 (6.44) 40.59 (4.64) 91.18 (11.45) 79.13 (15.76) 80.28 (19.91) 70.70 (11.09)
a1-ACT (mg/L) 1008.68 (124.83) 913.01 (176.05) 16557.89 (3569.36)* 617.21 (26.11) 1431.98 (677.58) 2206.62 (849.88)
a1-ACT (mg/mg albumin) 131.21 (26.58) 111.70 (21.56) 560.68 (84.62)** 78.10 (15.21) 122.83 (22.26) 213.93 (47.94)*
a1-ACT (mg/g Creatinine) 888.73 (133.56) 778.05 (108.90) 20200.2 (4503.22) ** 942.92 (84.48) 1959.31 (1534.83) 2125.57 (401.41) *
a1-microglobulin (mg/g
Creatinine)
13.17 (6.45) nd 53.86 (54.02) 5.83 (1.56) 37.33 (24.76) nd
a1-microglobulin (mg/g
Creatinine)
3.11 (1.44) nd 4.40 (1.05) 0.44 (0.19) 3.23 (0.52)** nd
Cystatin C and a1-ACT were measured in patient urine by ELISA and expressed as quantities per ml urine or relative to concentrations of albumin and creatinine. Values
obtained from sCJD patient urine are directly comparable to values obtained from urine of AD patients and the healthy control group A consisting of patients of
comparable age and gender distribution. Control group B represents a comparable control group for the vCJD measurements, consisting of patients initially suspected
to have CJD but being later determined not to have CJD. Control group C consists of patients either pre-transplant with kidney disease, patients post-kidney transplant
and patients with bladder carcinomas and nephritic inflammation. Numbers in parenthesis represent S.E.M. nd, not done.
doi:10.1371/journal.pone.0003870.t003
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plasma (See Table 2), alterations may simply reflect general
proteinuria resulting from compromised renal function. We
addressed this in several ways. Firstly, prospectively recruited
patients with known macro- or microhaematuria, or proteinuria,
and retrospectively collected urine samples with albuminuria of
$150 mg/ml, were excluded from further analysis. Secondly, we
obtained urine from an additional set of patients (control group C)
which predominantly included post-kidney-transplant patients
following diabetic nephropathy or focal segmental glomeruloscle-
rosis and reflux nephropathy. Thirdly, we investigated urine from
patients presenting with bladder carcinoma, and with pyelone-
phritis with bacteriuria (Control group C). These groups also
served to assess the specificity of the changes observed in the CJD
groups relative to other non-neurological conditions.
Since many factors can affect urine concentration and,
consequently, concentration of test substances, we normalized
cystatin C and a1-ACT concentration against urinary creatinine.
In the absence of renal dysfunction, the excretion rate of creatinine
is relatively constant and has been used for adjusting urine
concentration/dilution effects in measurement of urinary metab-
olites [28]. Normalization to creatinine therefore controls for both
potential variations in urine concentration between individuals in
spot-test urine samples and renal function. For these reasons we
also expressed cystatin C and a1-ACT concentrations relative to
both albumin and creatinine (Table 3). Urinary a1-ACT levels
were evident in sCJD patients regardless of normalization to
urinary albumin or creatinine. Additionally, we observed that
neither age, sex or study centre sampling location were variables
contributing to elevated urinary a1-ACT levels in sCJD patients
(not shown).
Since ELISA results can be confounded by crossreactive
contaminants, we performed Western blotting analyses on selected
urine samples. These confirmed dramatically elevated immunore-
active bands with the electrophoretic motility of a1-ACT in sCJD
patients (Fig. 4A).
In contrast, we observed no statistically significant alteration in
urinary cystatin C between sCJD or vCJD groups and respective
controls, regardless of whether cystatin C concentration was
expressed as raw, non-normalized data, or relative to either
urinary albumin or creatinine (Table 3).
In addition, urinary a1-ACT was also significantly higher in
sCJD patients compared to control group C when expressed either
relative to albumin or creatinine (Table 3, p,0.001).
When sCJD patients were compared to control groups A, C,
and AD patients, the sensitivity and specificity of elevated urinary
a1-ACT for sCJD were, respectively, 72.4%, 87.5% (mg/mg
albumin) or 89.7%, 100% (mg/g creatinine) if Control group C is
not included in the calculation, and 79.3%, 94.7% (mg/mg
albumin) or 96.6%, 100% (mg/g creatinine) if Control group C is
included in the calculation (Fig 5). In contrast to the data obtained
for sCJD patients, we observed no significant alterations in urinary
a1-ACT from vCJD patients referenced to control group B
(Table 3, Figure 3).
Longitudinal measurements of two sCJD patients presented to
the NRPE (one definite and one probable sCJD) revealed a
progressive increase in urinary a1-ACT relative to both albumin
and creatinine throughout the clinical course of disease (Fig. 4B).
This finding suggests that urinary a1-ACT excretion may be useful
for monitoring disease progression, (e.g. in therapeutical trials) as a
responsive surrogate biomarker.
As a further indication of renal proximal tubule function, we
measured urinary levels of a1-microglobulin in the sCJD and
vCJD groups relative to respective control groups. The concen-
tration of a1-microglobulin, normalized to creatinine or albumin,
were not significantly altered in sCJD urine (Table 3), yet
appeared to be higher in urine of vCJD patients than in
appropriate controls (p,0.001). Normalization of values to both
albumin and creatinine, and comparison to control group C,
indicates that the observed increase in urinary a1-ACT concen-
trations in sCJD patients is independent of renal function. We also
retrospectively assessed plasma creatinine and urea levels in 19
CJD patients presented to the NRPE. This analysis did not bring
forward any evidence that gross renal impairment may represent a
general feature of late-stage sCJD (Table 4).
Urinary a1-ACT in field cases of animal prion diseases
We carried out Western blot analyses of urine from scrapie-sick
sheep, cattle with confirmed Bovine Spongiform Encephalopathy
(BSE) and deer with confirmed Chronic Wasting Disease (CWD),
along with urine from healthy animals collected post-mortem
(Fig. 6A–C). In addition, we analyzed by Western blot urine
samples collected sequentially from one sheep that was pre-
clinically infected with scrapie and went on to display clinical signs
of disease. Scrapie was confirmed post-mortem in this sheep by
histopathology and Western blot analysis of brain tissue (data not
shown). Urine from the latter sheep was analyzed at 10, 9, 2 &
1 months prior to the development of terminal scrapie, together
with urine from six sheep unaffected by scrapie (Fig. 6D). Urinary
a1-ACT was increased 2 months before terminal disease, and
remained sustained thereafter.
We also observed significantly elevated levels of urinary a1-ACT
in two of six BSE-affected cattle (Fig. 6B) and in one of two CWD-
affected deer (Fig. 6C). One animal from the sheep study shown in
Fig. 6A was culled following appearance of scrapie-like symptoms.
However, post-mortem biochemical and pathological confirma-
tion was inconclusive, and this particular animal was classified as
‘‘atypical’’ scrapie. It is therefore unclear whether elevated urinary
a1-ACT in this animal represents a false positive, or the
identification of a scrapie case hitherto unqualified by other
biochemical and histological techniques.
Discussion
A global microarray screen of scrapie-infected mouse brains
identified a limited number of genes undergoing transcriptional
elevation well before the clinical onset of disease. One of these was
Serpin-a3n, which encodes the serine proteinase inhibitor a1-
antichymotrypsin (a1-ACT). Its transcription was drastically
elevated not only in whole-brain homogenates of scrapie-infected
mice, but also in occipital cortices of sCJD patients. These
Figure 2. Western blot analysis of cystatin C in the CSF of
patients suffering from sCJD. Equivalent amounts of CSF protein
(10 mg) from late-stage sCJD patients and from appropriate age-
matched non-sCJD patients were fractionated under non-reducing SDS-
PAGE conditions and analyzed by Western blot using a polyclonal anti-
human cystatin C antibody. No difference was found in CSF cystatin C
levels of sCJD patients vs. controls.
doi:10.1371/journal.pone.0003870.g002
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Figure 3. Urinary a1-ACT and creatinine levels. a1-ACT levels (mg/L) were plotted relative to creatinine levels (g/L) for (a) sCJD patients together with
Control group A, AD, and Control group C patients and (b) vCJD patients together with respective Control group B patients. Error bars represent s.e.m.
doi:10.1371/journal.pone.0003870.g003
Prion Disease Biomarker
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observations suggest that a1-ACT elevation occurs in prion
infections of many species.
Serpin-a3n encodes a secretory leader peptide, and a1-ACT is
present in body fluids. This raised the possibility that a1-ACT may
represent a candidate biomarker of prion infection. Since many
brain metabolites are found in the CSF, we first tested whether
CSF concentrations of a1-ACT would predict prion infection.
Indeed, sCJD patients exhibited a highly significant (p,0.001)
increase of a1-ACT in CSF when normalized against total CSF
protein and compared to appropriate age-matched controls.
a1-ACT is elevated in brains of AD patients and contributes to
AD amyloid plaque deposits [17,18], but the value of a1-ACT as a
biomarker of AD is unclear. Some studies have reported elevated
a1-ACT in plasma or CSF of AD patients [19,20,21,22], whereas
others found no changes [29]. In agreement with the latter study,
we found no increased a1-ACT in plasma and CSF of AD patients
in the present study.
We then sought to compare the diagnostic value of a1-ACT with
that of cystatin C, which had been claimed to be a biomarker for
CJD. We found that plasma and CSF levels of cystatin C did not
discriminate between AD patients and age and gender-matched
control patients, in agreement with previous findings [30]. Also,
CSF measurements of cystatin C by sandwich ELISA in large
collectives of sCJD, vCJD, and control samples was not discrim-
inatory between these three groups. The latter finding is at striking
variance with two studies of cystatin C in the CSF of small
collectives of CJD patients (n= 8 and 6, respectively) [15,16]
reporting up to 30-fold increases of CSF cystatin C in sCJD patients.
Cystatin C undergoes proteolytic processing, and a 12.5 kDa
cleavage product was reported to be elevated in the CSF of
patients suffering from multiple sclerosis, even if the levels of full-
length 13.4 kDa cystatin C were unaltered [31]. Therefore,
antibodies differentially recognizing cystatin C and its degradation
products may introduce a confounding factor. However, we were
unable to demonstrate any differences in cystatin C levels in CSF
of sCJD patients by Western blotting even when using the same
antibody that had led to the claim of a 30-fold elevation of CSF
cystatin C in sCJD patients [16]. We conclude that CSF cystatin C
is unaltered in the collective of patients investigated here (n = 8)
and therefore does not represent a biomarker of sCJD or vCJD.
Figure 4. Urinary a1-ACT of sCJD patients. (A) Equivalent amounts (50 mg) of urinary protein from sCJD patients and appropriate age-matched
controls were fractionated under non-reducing SDS-PAGE conditions and subsequently analyzed by Western blot using an anti-human a1-ACT
monoclonal antibody. A duplicate blot incubated with HRP-labeled secondary antibody alone is shown. To verify equivalent protein loading, blots
were stripped and re-probed with anti-albumin antibodies. Molecular weight marker positions are indicated. a1-ACT levels are significantly higher in
sCJD patient urine, corroborating the data obtained by ELISA measurement. (B) ELISA measurement of a1-ACT in urine collected sequentially during
the clinical phase of disease of two sCJD patients (represented as circles or triangles) indicates a progressive increase in a1-ACT levels normalized
both for albumin and creatinine. Error bars represent the standard deviations in replicate measurements of each sample.
doi:10.1371/journal.pone.0003870.g004
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We then studied the occurrence of immunoglobulins, a1-ACT,
and cystatin C in urine samples. We were unable to confirm the
previously reported presence of protease-resistant immunoglobulin
light chains in the urine of prion-affected animals and humans
[32,33,34]. Our use of anti-mouse IgG2a as secondary antibody
rather than total IgG may account for this discrepancy. Also,
cystatin C excretion was unaltered urine of AD, sCJD, and vCJD
patients regardless of the normalization method used, and
therefore not diagnostic of prion infection.
Surprisingly, urine samples from sCJD patients belonging to the
UK, German and Swiss collectives displayed consistently elevated
a1-ACT. Significance was attained independently of whether
ELISA results were expressed as raw concentrations, or normal-
ized against creatinine or albumin. ROC curve analysis confirms
Figure 5. Receiver Operating Characteristic (ROC) Curve Analysis. ROC curves were calculated for mg a1-ACT/mg albumin (a & c) or mg a1-
ACT/mg creatinine (b & d) for sCJD patients relative to either Control group A and AD patients (a & b) or Control group A, AD and Control C patients
(b & d). Sensitivity, specificity, and threshold (criterion) for each are indicated.
doi:10.1371/journal.pone.0003870.g005
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high specificity and sensitivity of the ability of urinary a1-ACT
measurement to discriminate sCJD status. In a ROC curve the
true positive rate (Sensitivity) is plotted in function of the false
positive rate (100-Specificity) for different cut-off points. Each
point on the ROC plot represents a sensitivity/specificity pair
corresponding to a particular decision threshold. A test with
perfect discrimination (no overlap in the two distributions) has a
ROC plot that passes through the upper left corner (100%
sensitivity, 100% specificity). Therefore the closer the ROC plot is
to the upper left corner, the higher the overall accuracy of the test.
The a1-ACT ELISA assay predicted prion infection with excellent
sensitivity and specificity. The highest degree of sensitivity and
specificity was observed for urinary a1-ACT normalised to
creatinine. Vastly increased excretion of a1-ACT observed by
ELISA-based measurement, this was also confirmed by Western
blot analysis.
The enhanced excretion of a1-ACT in prion infections is
surprising. In view of the unaltered plasma a1-ACT levels of sCJD
patients, a1-ACT ‘‘spillover’’ from blood to urine is unlikely to
underlie our observations. We therefore considered, and attempt-
ed to control for, possible artifactual effects. First, we considered
that increased a1-ACT excretion may result from glomerular
dysfunction. However, normalization of data to either urinary
creatinine or albumin, which would be increased in many renal
diseases, did not affect the results. Secondly, urinary cystatin C, a
marker of glomerular filtration rate [35], was unaltered in sCJD
patients, suggesting that increased a1-ACT excretion does not
result simply from compromised renal function. Thirdly, elevated
a1-antichymotrypsin levels in sCJD urine are unlikely to result
from proximal tubule defects, since urinary a1-microglobulin levels
were not significantly different in urine of sCJD patients relative to
respective controls. Fourthly, our retrospective analyses of sCJD
patient plasma creatinine and urea indicate that renal insufficiency
is not a typical feature of late-stage sCJD patients (Table 4).
Finally, urinary a1-ACT levels were significantly higher in sCJD
than (1) in post-kidney transplant subjects following diabetic
nephropathy, focal segmental glomerulosclerosis, and reflux
nephropathy, (2) in patients with bladder carcinoma, and (3)
patients with pyogenic nephritis leading to bacteriuria. These
aggregated data argue against increased levels of a1-ACT in urine
from sCJD patients simply resulting from renal disease, or from
generally compromised health.
We considered that enhanced a1-ACT detection may result from
sample collection or processing anomalies. We deem this unlikely for
a number of reasons. Firstly, high urinary a1-ACT was diagnostic in
sCJD patient collectives from each of three separate national
reference centers. Secondly, no alterations of a1-ACT concentration
in test urine were found when comparing voided vs. non-voided
(P.0.05) urine, pre- vs. post-pellet urine (P.0.05), and urine samples
collected in the morning or evening (P.0.05). Thirdly, the a1-ACT
ELISA yielded similar results whether urines was stored immediately
at280uC or left at room temperature or 4uC overnight before testing
(P.0.05). Therefore, none of the common sample collection and
processing artifacts account for the reported results. Finally, elevated
urinary a1-ACT was evident in a number of BSE-affected cattle,
CWD-affected deer, and scrapie-affected sheep. In the latter, it was
diagnostic at least 2 months prior to terminal disease.
Enhanced a1-ACT excretion may prove useful for correlating
responsiveness to experimental therapeutic regimens and perhaps
for biochemical discrimination of vCJD from sCJD without
invasive biopsies. Finally, considering its excellent specificity and
good sensitivity, one might consider exploring the usefulness of
urinary a1-ACT determinations as a means of deferring blood
units from asymptomatic donors who may be harboring preclinical
prion infections.
Materials and Methods
Prion inoculations
Mice were maintained under specific pathogen-free conditions.
Eight week-old inbred C57Bl/6 mice were inoculated intraperi-
toneally with 100 ml (6 log LD50 units) of the Rocky Mountain
laboratory (RML) scrapie strain (passage 5 in CD1 mice, hence
called RML5) prepared as a 10% (w/v) clarified brain homoge-
nate containing 5% BSA. The titer of this standard RML5
inoculum was 8.9 log LD50 g21 of brain tissue [36]. Age- and
gender-matched control mice were inoculated intraperitoneally
with 100 ml of a 10% (w/v) clarified brain homogenate from
healthy CD1 mice. The incubation period of this model until onset
of terminal disease was approximately 200–210 days post
inoculation (dpi). Tissues from mice at 45, 100, 145 and 190 dpi
stages of pathogenesis were used for real-time quantitative RT-
PCR analyses. All manipulations were approved by the Animal
Experimentation Committee of the Canton of Zu¨rich.
Tissue collection and RNA isolation
Human occipital cortex tissue was provided via the Swiss
Reference Center for Prion Diseases (NRPE) and was collected at
Table 4. Selected NRPE sCJD patient plasma creatinine and
urea levels.
NRPE
Patient ID
sCJD
status
Plasma Creatinine
(52–114 mmol/L)
Plasma Urea
(2.9–7.7 mmol/L)
217 Definite 58 3.6
222 Definite 113 nd
223 Probable 71 6.7
228 Definite 70 nd
233 Definite 81 5.5
234 Definite 124* 12*
238 Definite 92 nd
239 Definite 52 4
240 Probable 85 nd
246 Definite 95 10.3*
247 Definite 100 7.4
248 Definite 75 3.6
249 Definite 96 6.1
257 Probable 70 5.5
260 Definite 88 3.6
262 Definite 78 nd
268 Definite 72 nd
270 Probable 74 nd
271 Definite 61 4.5
Gross indication of renal function in sCJD patients was assessed by
retrospective analysis of plasma creatinine and urea levels measured as part of
the clinical assessment of sCJD patients. Normal reference ranges are indicated.
Data obtained from patients during the clinical phase of disease and which
have subsequently died and been confirmed post-mortem as definite sCJD are
indicated. Those patients which are either still alive, or which have died but did
not undergo post-mortem, are indicated as probable sCJD. Patients with
plasma creatinine or urea levels out-with this expected range are indicated by
an asterisk. Patients for which creatinine or urea measurements were not
obtained are indicated (nd; not done)
doi:10.1371/journal.pone.0003870.t004
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autopsy from a cohort of Swiss patients who died between 1996
and 2004. Patients with prion disease, Alzheimer’s disease and
patients without neurologic disorders were included. Tissues were
processed according to established guidelines regarding safety and
ethics and periods from death until post-mortem tissue collection
were approximately 4–18 hours. All tissues were snap-frozen in
liquid nitrogen prior to long-term storage at 280uC. Tissues from
the RML murine model of prion pathogenesis were collected at
various stages throughout pathogenesis. All murine tissues were
immediately snap-frozen in liquid nitrogen prior to storage at
280uC until required. Total RNA was isolated using Trizol
(Invitrogen AG, Switzerland) from eight patients of each control,
AD and sCJD group.
Preparation of labeled cRNA and microarray
hybridization
All procedures for preparation of labelled cRNA probes and
subsequent Genechip hybridisations were performed according to
suggested Affymetrix guidelines (http://www.affymetrix.com). To-
tal RNA isolated from whole brain using Trizol was subjected to a
purification step (RNeasy mini kit, Qiagen, Switzerland). Quality of
total RNA was assessed by agarose gel electrophoresis. Equal
amounts of total RNA from 3 individual brains of mice at 145 dpi
stage of prion pathogenesis were combined to act as template for
generation of probe for one biological replicate. Thus, from nine
mock-inoculated and nine prion inoculated mice, a total of three
sets of labelled cRNA probes were synthesized representing three
biological replicates. Double-stranded cDNA was synthesized using
20 mg total RNA as template (cDNA Synthesis kit, Cat.No.11917-
010, Invitrogen, Switzerland) and primer 59-GGCCAGT-
GAATTGTAATACGACTCACTATAGGGAGGCGG(dT)24-39.
Biotin-labeled cRNA was synthesized, using Enzo BioArray High-
Yield RNA transcript labeling Kit (T7) (Enzo Life Sciences,
Germany), purified using the RNeasy mini kit and quantified by
spectrophotometry. Quality was assessed by agarose gel electro-
phoresis. Typical yields were in the range of 120–150 mg labeled
cRNA. 15 mg of labeled cRNA was fragmented in 40 mM Tris-
acetate, 100 mM KOAc, 30 mM MgOAc, pH 8.1 at 95uC for
35 min. Following fragmentation, an aliquot of one representative
of the replicates of each sample was hybridized to Affymetrix Test3
arrays to determine the quality of the probes, reflected by the 39/59
ratios, and to test all buffers using conditions outlined in the
Affymetrix expression analysis manual. The samples were then
hybridized to Affymetrix MOE430A and MOE430B chips. All
hybridizations were carried out for 16 h at 45uC at 60 rpm. Chips
were then washed and incubated with streptavidin-phycoerythrin
according to the manufacturers instructions on the Affymetrix
GeneChip Fluidics Station 450 with and scanned using the
Affymetrix GS Scanner 2500 in conjunction with Affymetrix
Microarray Suite 5.0 software.
Figure 6. Western blot analysis of urinary a1-ACT from natural field cases of prion disease. Equivalent amounts of urinary protein from
natural terminal field cases of (A) sheep scrapie (65 mg), (B) cattle BSE (30 mg), (C) deer CWD (90 mg) and (D) pre-mortem sheep scrapie (65 mg),
together with urinary protein from appropriate healthy controls, were fractionated under reducing SDS-PAGE conditions and subsequently analyzed
by Western blot using an anti-human a1-ACT monoclonal (A, B & D) or polyclonal (B) antibody. In each case a duplicate blot incubated with HRP-
labeled secondary antibody alone was also prepared and is shown. To verify equivalent protein loading, blots were stripped and re-probed with an
anti-human albumin antibody. Recombinant a1-ACT (30 ng) was loaded as positive control. Molecular weight marker positions are indicated. Panel A,
lane 8 represents urine from a suspected scrapie case, the precise status of which is unclear (U) at present. Pre-terminal sheep scrapie urine (D) was
analyzed from six individual healthy sheep and from one case at 10, 9, 2 & 1 months prior to being sacrificed at end-stage of disease (lanes 8–11
respectively).
doi:10.1371/journal.pone.0003870.g006
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Microarray Data Analysis
Intensity values of all chips were normalized with dChip
software (http://www.dchip.org) [37] and applying the model-
based expression analysis algorithm (PM-only or PM/MM model)
the expression values were calculated.
Global brain gene expression profiles from mice 145 days post-
inoculation, with either mock inoculum or the RML prion strain,
were compared applying a 1.3-fold change as the lower limit, lower
90% confidence boundary of fold change and p values of ,0.05.
Only those genes were considered which were flagged present in
100% of chips from cRNA probes derived from at least either mock
or prion inoculated mice. Microarray datasets are available at www.
ncbi.nlm.nih.gov/geo; accession number GSE7207.
Northern Blot Analyses
Northern blot hybridisation experiments as previously described
[38] using 15 mg total RNA. Random primed [a32P]dCTP probes
were prepared from 20 ng of gel-purified DNA homologous to
target transcripts using Rediprime II random priming kit
(Amersham Biosciences, Switzerland) and purified with Nick
Sephadex G50 columns (Amersham Biosciences, Switzerland).
Prehybridization and hybridization was performed overnight at
42uC using Ultrahyb (Ambion, USA), containing 16106 cpm/ml
radiolabelled probe and 100 mg/ml denatured herring sperm
DNA (Catalysis AG, Switzerland) and 20 mg/ml denatured yeast
tRNA (Sigma Fluka, Switzerland). Post-hybridization washes were
performed according to Ultrahyb instructions. Hybridization
signals were quantified using Fujifilm imaging plate technology
(BAS-1800II, Fujifilm, Japan) and normalized for variations in
RNA loading by subsequent probing with an excess of 18S rRNA
cDNA probe [38].
Probes and accession numbers
Murine cDNAs for derivation of probes for Serpin-a3n and
Gfap were obtained from Open Biosystems (www.openbiosystems.
com); accession numbers were BI145274 and AI836096 respec-
tively.
Quantitative Real-Time PCR (QPCR)
In all cases 5 mg of total RNA was used as template for first-
strand cDNA synthesis. Prior to cDNA synthesis, residual genomic
DNA was removed by the DNA free-kit (Ambion, USA). Total
RNA was converted into cDNA using the bulk first strand cDNA
synthesis kit and Not I-(dT)18 as primer (Amersham Biosciences
Europe GmbH, Germany). Control reactions omitting reverse
transcriptase were performed to validate successful removal of
contaminating genomic DNA. Successful cDNA synthesis and lack
of contamination with genomic DNA was tested by performing
PCR (40 cycles) with primers specific for b-actin. All samples
utilized for QPCR analysis were validated free of contaminating
genomic DNA. Quantitative real-time PCR was performed using
the SYBR Green PCR Master Mix (Qiagen AG, Switzerland) on
an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems, Switzerland) using default cycling conditions. For
murine samples, triplicate reactions of three biological replicates
were utilized. In the case of human material, triplicate reactions
were performed for each sample. Expression levels of serpin-a3n/
a1-ACT were normalized to b-actin. Primer sequences were as
follows: 59- tatctgcctccacccaaaag-39 & 59- gccagatgtggacaaagtga-39
(murine serpin-a3n), 59-atggatgacgatatcgctg-39 & 59-atgaggtagtctgt-
caggt-39 (murine ActB), 59-tctcccaggtggtccataag-39 & 59-ttactga-
gagccccactgct-39 (human a1-ACT), 59-ggacttcgagcaagagatgg-39 &
59-agcactgtgttggcgtacag-39 (human ACTB).
Enzyme-linked immunosorbent assays for a1-
antichymotrypsin (a1-ACT)
Human a1-ACT was measured by triple antibody sandwich
ELISA. Microtiter plate wells (Nunc F96 Maxisorb, Milan
Analytica, Switzerland) were coated with 100 ml of 5.4 mg/ml
affinity purified rabbit anti-human a1-ACT (Dako, Switzerland) in
carbonate-bicarbonate buffer, pH 9.6. The plates were then sealed
and incubated overnight at 4uC. After six washes with phosphate-
buffered saline (PBS) containing 0.05% Tween-20 (PBST) the
remaining binding sites in the wells were blocked by incubating
with 100 ml of PBST containing 5% bovine serum albumin (BSA,
Sigma) for 2 h at room temperature with shaking, followed by six
washes with PBST. Thereafter, 100 ml of purified recombinant
human a1-ACT (R&D Systems, UK), in several dilutions ranging
from 0 to 200 ng/ml to generate a standard curve, and test
samples were added. Standard curve and test samples were diluted
into PBS sample buffer containing a final concentration of 0.05%
Tween-20 and 1% BSA. Serum, CSF and urine were diluted
1:250 000, 1:3000 and 1:300 respectively such that all samples
were contained within the measurable range of the standard curve.
Standard curve and test sample dilutions were prepared in
triplicate. The plates were sealed and incubated at room
temperature for 2 h at room temperature with shaking and
washed six times with PBST. Then 100 ml of sheep anti-human
a1-ACT (The Binding Site, UK), diluted to 31 mg/ml in PBST
containing 1% BSA, was added to each of the wells and the plate
sealed and incubated for 2 h at room temperature with shaking.
Following a further six washes with PBST 100 ml of horseradish
peroxidase (HRP) conjugated donkey anti-sheep IgG, diluted
1:1000 in PBST containing 1% BSA, was added to each well and
the plate sealed and incubated at room temperature for 2 h.
Following a final six washes with PBST 100 ml of 3,39,5,59-
teramethylbenzidine chromogenic substrate (TMB, Invitrogen,
UK) was added to each well. Following colour development
100 ml of H2SO4 was added to each well to stop the reaction and
the optical density measured at 450 nm or 405 nm in an ELISA
micro-plate reader. Values were expressed as concentration per ml
fluid (plasma, CSF & urine), relative to total protein (plasma &
CSF) or relative to creatinine and albumin (urine). Inter- and
intra-assay correlation of variance was 7.36% and 3.84%
respectively.
Enzyme-linked immunosorbent assays for cystatin C
Measurement of human cystatin C was performed using a
commercial sandwich ELISA kit (Biovendor Laboratory Medicine
Inc., Czech Republic) according to the manufacturer’s instruc-
tions. Human cystatin C standard curve and test samples were
diluted into PBS sample buffer containing a final concentration of
0.05% Tween-20 and 1% BSA. Serum, cerebrospinal fluid (CSF)
and urine were diluted 1:300, 1:1000 and 1:100 respectively such
that all assay values were contained within the measurable range
of the standard curve. Standard curve and test sample dilutions
were prepared in triplicate. Optical density was measured at
450 nm or 405 nm in an ELISA micro-plate reader. Values were
expressed as concentration per ml fluid (plasma, CSF & urine),
relative to total protein (plasma & CSF) or relative to creatinine
and albumin (urine).
Albumin & a1-microglobulin
Measurements of human urinary albumin and a1-microglobulin
were performed using a commercial competitive ELISA for
albumin (Orgentec Diagnostika, Germany) and a sandwich ELISA
format for a1-microglobulin (ImmunDiagnostik, Germany) ac-
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cording to the manufacturer’s instructions. Optical density was
measured at 450 nm in an ELISA micro-plate reader. Values were
expressed as concentration per ml urine (albumin) or normalized
to albumin or creatinine (a1-microglobulin).
Urinary creatinine
Measurement of urinary creatinine was performed using a
commercial kit (Cayman Europe, Estonia) based on the Jaffe
alkaline picrate reaction according to the manufacturer’s instruc-
tions. Urine samples were diluted 1:15 in molecular biology grade
water such that assay values were contained within the measurable
range of the standard curve. Optical density was measured at
490 nm in an ELISA micro-plate reader. Values were expressed as
concentration per ml urine.
Western blots
Total protein concentration was determined by bicinchoninic
acid (BCA) or microBCA (Perbio Science, Switzerland). Equal
amounts (mg) of total protein were separated by electrophoresis
through 12% SDS-PAGE gels and transferred to nitrocellulose
membranes. Reducing conditions were used in all cases except for
detection of human a1-ACT. The membranes were blocked in
PBST containing 5% non-fat milk for 2 h at room temperature
prior to incubating overnight at 4uC with primary antibody.
Following six minute washes with PBST the membranes were
incubated in PBST containing 5% non-fat milk and the
appropriate secondary antibody for 1 h at room temperature. In
the case of cattle urine, Top-block (GE Healthcare, UK) was used
instead of 5% non-fat milk. As a positive control, purified
recombinant human a1-ACT (R&D Systems, UK) was also
included.
For detection of a1-ACT in human, sheep and deer urine,
murine anti-human a1-ACT (R&D Systems, UK) was used at a
concentration of 2 mg/ml followed by incubation with HRP-
conjugated rabbit anti-mouse IgG2a (Invitrogen, UK) at a dilution
of 1:5000. For detection of a1-ACT in cattle urine, rabbit anti-
human a1-ACT (Dako, Switzerland) was used at a dilution of
1:1000, followed by incubation with HRP-conjugated donkey anti-
rabbit IgG (GE Healthcare, UK) at a dilution of 1:1000. For
detection of cystatin C in human CSF, samples were prepared
under non-reducing conditions, electrophoresed and transferred to
nitrocellulose membranes. After blocking as outlined above,
membranes were incubated in PBST containing 5% non-fat milk
and a 1:1000 dilution of rabbit anti-human cystatin C (Upstate,
UK), followed by washing with PBST and incubation with HRP-
conjugated donkey anti-rabbit IgG (GE Healthcare, UK) at a
dilution of 1:1000. Following addition of ECL substrate (Perbio,
Switzerland) signal was visualized using a VersaDoc model 4000
Imaging system (BioRad, Switzerland). Membranes were stripped
(Western blotting stripping solution, Socochim, Switzerland) and
re-probed with rabbit anti-human albumin (Abcam, UK), at a
dilution of 1:5000, followed by HRP-conjugated donkey anti-
rabbit IgG (GE Healthcare, UK), at a dilution of 1:1000, and
subsequent ECL detection as outlined above.
Body fluid samples of patients
Samples were obtained from patients who presented to the
NRPE, the United Kingdom CJD Surveillance Unit (CJDSU), the
German Reference Centre for Prion Diseases, the Clinic for
Nephrology, the Institute for Clinical Pathology, and the Division
of Psychiatric Research at University of Zu¨rich. Collection of
blood, CSF and urine for subsequent analysis was approved by the
Swiss Federal Office of Health.
For control, we assembled two distinct groups of persons.
Control group A consisted of individuals whose age and gender
matched those of patients suffering from sCJD or AD, whereas the
demographics of control group B matched patients suffering from
variant CJD (vCJD). Specifically, control group B consisted of
patients who initially presented to the UK CJDSU with suspected
CJD, but were later determined to suffer from other ailments.
Urine and CSF samples were obtained from patients at varying
clinical stages of CJD, from mid-clinical stage to terminal disease. In
the case of terminal patients, body fluids were collected at post-
mortem. Plasma was derived from patients ante mortem. From pre-
mortem patients where sCJD was suspected, samples were included
in the study only following post-mortem confirmation of sCJD.
In addition, we investigated a control group consisting of urine
collected from patients post-kidney transplant following diabetic
nephropathy, focal segmental glomerulosclerosis and reflux
nephropathy conditions, from patients presenting with bladder
carcinoma and bacteriuria, and from patients with cerebrovascu-
lar disease or encephalitis.
Urine from patients with known macro- or microhaematuria, or
proteinuria, was excluded from further analysis. In retrospectively
collected urine samples in which this was unknown, samples
containing .150 mg/ml albumin were excluded from the study.
Within approximately 18 h of collection, urine was centrifuged
briefly, aliquoted and stored at 280uC until analysis. Blood was
collected in tubes containing citrate to a final concentration of
0.5% and, within 12 h of collection, centrifuged a 2 280 g for
4 minutes at room temperature. The plasma layer was aliquoted
and stored at 280uC until required. Cerebrospinal fluid was
collected, aliquoted and stored at 280uC. Informed consent was
obtained in all relevant cases.
Field Animals
Urine samples were obtained from sheep scrapie cases both pre-
terminal (without the use of diuretic drugs or catheter) or at post-
mortem via bladder puncture. Urine from deer CWD and cattle
BSE cases (and controls) were obtained at post-mortem by bladder
puncture. Pre-terminal scrapie cases consisted of six healthy Sarda
sheep held in the Sassari region of Italy (PRNP genotypes: ARR/
ARQ, ARQ/VRQ, ARR/ARR, ARQ/ARQ) and one natural
scrapie positive animal (ARQ/ARQ), from which urine was
collected pre-clinical and throughout the clinical phase of disease.
Urine from terminal sheep was derived from UK sheep of the
Suffolk breed and consisted of males and females displaying no
clinical signs of scrapie (ARR/ARR and ARQ/ARQ PRNP
genotypes) and natural scrapie positive males and females (ARQ/
ARQ PRNP genotypes).
Statistical tests
Data was analyzed for statistical significance using two-tailed
unpaired Mann-Whitney t-test with 95% confidence interval.
Significance of p,0.05, and p,0.001 is indicated by * and **
respectively. Receiver operator characteristic (ROC) curves were
calculated and plotted using the software MedCalc.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0003870.s001 (0.08 MB
XLS)
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